Sialic acid and cancer immunotherapy

In experiments with breast cancer cells grown in lab dishes, researchers report that antibody-enzyme conjugates, composed of the therapeutic antibody trastuzumab coupled to an enzyme that selectively removes sialic acid, a sugar found on normal cells, from the surface of tumor cells, enhanced tumors’ susceptibility to destruction by immune cells, providing a potential tool for cancer immunotherapy, particularly for patients with trastuzumab resistance. - Read at PNAS.org

Article #16-08069: “Precision glycocalyx editing as a strategy for cancer immunotherapy,” by Han Xiao, Elliot C. Woods, Petar Vukojicic, and Carolyn R. Bertozzi.